Abstract | AIMS/HYPOTHESIS: METHODS: Pooled data from four placebo-controlled Phase 3 studies (N = 2,250) in patients with type 2 diabetes were used in the analyses. In each study, patients were treated with placebo, canagliflozin 100 mg or canagliflozin 300 mg, once daily for 26 weeks. Changes from baseline in body weight, HbA1c and SBP were measured at week 26, and the contribution of weight loss to the lowering of HbA1c and SBP was obtained using ANCOVA. RESULTS: CONCLUSIONS/INTERPRETATION:
|
Authors | William T Cefalu, Kaj Stenlöf, Lawrence A Leiter, John P H Wilding, Lawrence Blonde, David Polidori, John Xie, Daniel Sullivan, Keith Usiskin, William Canovatchel, Gary Meininger |
Journal | Diabetologia
(Diabetologia)
Vol. 58
Issue 6
Pg. 1183-7
(Jun 2015)
ISSN: 1432-0428 [Electronic] Germany |
PMID | 25813214
(Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Glycated Hemoglobin A
- Hypoglycemic Agents
- hemoglobin A1c protein, human
- Canagliflozin
|
Topics |
- Adult
- Aged
- Blood Pressure
(drug effects)
- Body Weight
(drug effects)
- Canagliflozin
(administration & dosage, therapeutic use)
- Diabetes Mellitus, Type 2
(blood, complications, drug therapy)
- Drug Administration Schedule
- Female
- Glycated Hemoglobin
(metabolism)
- Humans
- Hypertension
(complications, drug therapy)
- Hypoglycemic Agents
(administration & dosage, therapeutic use)
- Male
- Middle Aged
- Systole
(drug effects)
- Weight Loss
|